example 494 [WO2014028479] parent molecule   Click here for help

GtoPdb Ligand ID: 12665

Compound class: Synthetic organic
Comment: This compound is claimed in patent WO2014028479, as a small molecule modulator of GRP6 activity [1]. It may be formulated as the trifluoroacetic acid conjugate. It is likely an antagonist or inverse agonist that reduces intracellular cAMP levels. Antagonism of GPR6 activity is being explored clinically, as a functional alternative to dopamine mediated activation of D2 receptors for conditions such as Parkinson's disease and other dyskinesias.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 52.35
Molecular weight 409.48
XLogP 1.79
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=C2C(=CC=N1)N=C(C(=N2)N3CCC(CC3)CC4=CC=C(C=C4F)F)NC5CC5
Isomeric SMILES CC1=NC=CC2=NC(NC3CC3)=C(N4CCC(CC5=CC=C(F)C=C5F)CC4)N=C12
InChI InChI=1S/C23H25F2N5/c1-14-21-20(6-9-26-14)28-22(27-18-4-5-18)23(29-21)30-10-7-15(8-11-30)12-16-2-3-17(24)13-19(16)25/h2-3,6,9,13,15,18H,4-5,7-8,10-12H2,1H3,(H,27,28)
InChI Key PWJURAYPJMGEQA-UHFFFAOYSA-N
References
1. Hitchcock S, Monenschein H, Reichard H, Sun H, Macklin T, Hopkins M. (2014)
Quinoxaline derivatives as gpr6 modulators.
Patent number: WO2014028479A1. Assignee: Envoy Therapeutics, Inc.. Priority date: 13/08/2013. Publication date: 20/02/2014.